key: cord-0283886-1ta9hsjc authors: Brunoni, A. R.; Digital tES group,; Fregni, F. title: Digitizing Non-Invasive Neuromodulation Trials: Scoping Review, Process Mapping, and Recommendations from a Delphi Panel date: 2022-03-05 journal: nan DOI: 10.1101/2022.03.03.22271837 sha: 2c25f18096d61515ba3d84158ca7bff0f1591eb9 doc_id: 283886 cord_uid: 1ta9hsjc Although relatively costly and non-scalable, non-invasive neuromodulation interventions are treatment alternatives for neuropsychiatric disorders. The recent developments of highly-deployable transcranial electric stimulation (tES) systems, combined with mobile-Health technologies, could be incorporated in digital trials to overcome methodological barriers and increase equity of access. We convened 61 highly-productive specialists and contacted 8 tES companies to assess 71 issues related to tES digitalization readiness, and processes, barriers, advantages, and opportunities for implementing tES digital trials. Delphi-based recommendations (>60% agreement) were provided. Device appraisal showed moderate digitalization readiness, with high safety and possibility of trial implementation, but low connectivity. Panelists recognized the potential of tES for scalability, generalizability, and leverage of digital trials processes; although they reached no consensus about aspects regarding methodological biases. We further propose and discuss a conceptual framework for exploiting shared aspects between mobile-Health tES technologies with digital trials methodology to drive future efforts for digitizing tES trials. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 5, 2022 . ; Transcranial electric stimulation (tES) is a non-invasive neuromodulation intervention that uses electric currents applied over the scalp to modify cortical activity and treat neuropsychiatric disorders, and has high safety and tolerability 1 . Notwithstanding, due to its low-to-moderate efficacy for several conditions, the consensus of its readiness for clinical use across indications varies 2,3 , and regulatory approvals across regions are mixed 4, 5 , warranting larger-scale clinical trials 6 . However, these trials are hampered by the need for daily visits to the research center to deliver the necessary number of tES sessions, which limits recruitment, harms adherence, increases costs 6 , and restricts diversity 7, 8 . Unlike other non-invasive neuromodulation modalities, tES devices, by virtue of being affordable and battery-powered 9 , are portable, making the intervention an appealing brain stimulation modality for patients who do not tolerate pharmacotherapy 10 or have difficulty attending for treatment at a clinical centre, In fact, several companies have been designing highly-deployable tES devices that could be used to address issues of scale, access, and patients' burden in the context of digital trials -i.e., trials that leverage aspects such as recruitment, assessment, and data analyses through the implementation of digital technologies 11 . These approaches could be further integrated with mobile Health devices, apps and wearables, allowing for several new implementations, such as simultaneous combination with cognitive and psychological interventions, ecological momentary assessment of behaviors, passive data collection, and digital phenotyping 12, 13 . However, since protocols and standards for digital trials using mobile tES are still emerging, the challenges and opportunities of their implementation processes have not yet been systematically examined. Moreover, issues on rigor and reproducibility -for instance, best practices to perform randomization, allocation concealment, and sham stimulation -and generalizability -how to fully explore their potential for scalability while ensuring adherence and representativeness -have only been discussed in non-digital contexts 7, 8, 14 . Finally, implementation challenges are different in low-/middle-income countries, which present lower digital literacy, fluence in non-native languages, and wireless connectivity 15 ; conversely, scalable mobile Health interventions have even higher impact potential in such countries 16 . Considering these challenges, we systematically identified non-invasive neuromodulation specialists to elaborate and discuss issues related to the extent, processes, and methodological characteristics of digitizing non-invasive neuromodulation trials. These findings, supplemented by a systematic scoping review of tES clinical research articles and an assessment of the digitalization degree of commercially available tES devices, provided a key summary of Delphi-based recommendations for enhancing the implementation of digital tES trials. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 5, 2022 Our protocol was pre-registered at the Open Science Framework (OSF) 17 and is depicted in figure 1. Minor deviations occurred (Sup. Material -Appendix 1). ( Figure-1) We used a Delphi technique, in which comments and feedback are iteratively discussed 18 , for addressing challenges and proposing recommendations for digitizing tES trials. Following recent papers 19, 20 , we initially convened a steering committee (SC) group, formed based on the collaborative network of the leading authors, to develop structured questionnaires with items using Five-point Likert scales or open questions (Supplementary Material -Appendix 2). The SC also provided qualitative feedback on several topics that was analyzed by the leading authors and qualitatively described here. Afterwards, the SC interacted with a larger expert panel (EP) to rate each item. The EP members were selected among the most productive authors in the field, identified through a systematic review of recent tES clinical trials in a 10-year span (Sup. Material -Appendix 3). Several interactions were performed between the EP and SC until a final manuscript version was assembled. Consensus was achieved by a >60% agreement of all panelists. Electronic questionnaires were used in all steps of this process. All members of the SC and the EP consented to have their names listed and identified in the manuscript. A systematic scoping review 21 was performed to identify tES reviews, consensus papers, and guidelines to select characteristics for composing the questionnaires used in the rating phase (Sup. Material -Appendix 4). Companies producing tES devices were identified through specialist referrals and web search and surveyed using structured questionnaires to assess their digitalization readiness, according to connectivity, readiness for digital trials, parameter space flexibility, ecological footprint, front-end interface, and data security (Sup. Process mapping and methodological assessment . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 5, 2022 We used SWOT (Strengths, Weaknesses, Opportunities and Threats) and SIPOC (Suppliers, Inputs, Process, Outputs, Customers) approaches to respectively identify external and internal negative and positive aspects for digitizing tES trials and map and compare processes related to standard and digital tES trials. The methodological assessment was based on perceived challenges and advantages, identified through questionnaires, of conducting such trials (Sup. Material -Appendix 2). This work received no specific funding from any source. For the SC, 34 authors were invited and all agreed to participate. For the EP, out of 43 authors who were identified, 14 did not reply to our contacts, and 2 declined to participate. Finally, 27 participants constituted the EP (Sup. Material -Appendix 6). Most panelists were men (70%), experienced (78% with > 10 years of experience in the field) and between 40 to 49 years-old (44% and 33% of the SC and the EP). They resided in the US (SC n=11, EP n=3), Brazil (SC n=6, EP n=5), Germany (SC n=5, EP n=4), and 13 other countries (Sup. Material -Appendix 7). Only 15% and 18% of the SC and EP members, respectively, were not conducting at least one tES trial with digital features; most were actually principal investigators (83%) of such trials. Our initial search yielded 443 references, and 34 articles met the inclusion criteria of our scoping review, including 9 recommendation articles 4,7,22-28 , 10 guidelines 3, 8, 14, [29] [30] [31] [32] [33] [34] [35] , 10 critical reviews 36-45 , and 5 expert consensus articles 6, 7, 35, 46, 472, [48] [49] [50] [51] , which were used for elaborating the study questionnaires (Sup. Material -Appendix 8). Eight of 13 companies contacted provided feedback. Digitization readiness varied according to their wireless connectivity, readiness for digital trials, flexibility of parameter space, ecological footprint, front-end interface, and data security. Markedly, current systems have limited wireless connectivity, which is a barrier for device-to-device communication with wearables and third-party apps that could enhance portability potential (eg, apps collecting biological data, and mobile mental Health apps). Conversely, most systems . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 5, 2022. ; https://doi.org/10.1101/2022.03.03.22271837 doi: medRxiv preprint currently present good data security protocols (reported HIPAA or GDPR compliance), flexibility of tES parameter space, and readiness for digital trials (figure 2). ( Figure-2) The identified characteristics and quantitative agreement rating composing the SWOT assessment is displayed in figure 3 . Qualitative aspects are briefly discussed here and detailed in the Sup. Material -Appendix 9. Regarding weaknesses, panelists agreed on two aspects: a) difficulties in remote supervision, raising concerns regarding patients themselves manipulating tES devices, which could lead to misuse, diversion of the device, or its use outside of medical contexts, further impacting on reproducibility of findings; b) and difficulties in obtaining accurate placement of electrodes, as deviations in electrode positioning and orientation might affect outcomes 9 . Therefore, companies should develop and test new methods for assuring correct placement of electrodes 26 . Other potential weaknesses did not reach consensus, such as concerns related to bioethics, particularly regarding equity to access; increased (compared to on-site tES trials) risks of common and serious adverse events 31 ; and relatively low evidence of clinical efficacy for most conditions 3 . Regarding opportunities, six aspects reached agreement: a) scalability, as, compared to on-site tES trials that need physical space, staff to apply sessions and commute of participants, digital trials using mobile tES devices do not have such constraints, allowing research assistants to monitor several participants at once, at any distance from the study centers; b) telemedicine, which has been widely adopted during the COVID-19 pandemic, facilitating its adoption in digital trials; c) employment of combined mobile Health technologies, permitting digital phenotyping 13 and combination with digital interventions when using paired wearables and smartphone applications; d) automatization of procedures (see SIPOC below); e) 5G / . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 5, 2022. ; https://doi.org/10.1101/2022.03.03.22271837 doi: medRxiv preprint Internet of Things, which can boost connectivity and data processing, leveraging data collection 13 and eventually allowing the development of mobile closed-loop tES systems 38 ; and f) use of design thinking approaches, i.e., customizing mobile tES devices around the patients´ perspectives 54 , for instance, to accommodate those with physical or cognitive impairments. Finally, two threats reached consensus: a) recreation and do-it-yourself misuse, which could lead to unexpected adverse events and safety issues 24 ; and b) regulatory status, as medical devices require formal regulatory approval in the US 55 and Europe 56 , although some tES devices are marketed as wellness devices, have regulatory device exemptions 5 , or can be approved by similarity 5 . Further, mobile tES devices could have additional regulations, if framed as mobile Health systems 57 . Additionally, two potential threats were identified by most of the panel, but did not reach the 60% consensus threshold: a) risks related to hacking and cyber-security, as observed in mobile Health devices 58 , and b) risks related to confidentiality and anonymity. We identified 4 main processes (recruitment, pre-screening, screening, and participation) in which digitization and automatization procedures can leverage mobile tES trials (Table 1 ). The panelists noted that trials might not be purely digital or analog, and different degrees of digital features can occur at each process. For instance, participants can be recruited through social media, but screened onsite. Moreover, digital processes can provide enhanced metrics to adjust processes, recruit faster, and follow participants for longer periods. Finally, digitization processes provide scalability due to the use of digital assessments and telemedicine. (Table 1) . ( Table-1 The panelists examined 24 methodological aspects of digital trials using mobile tES devices, reaching consensus in 12 of them (figure 4). They are briefly discussed here and detailed in the Sup. Material -Appendix 10. ( Figure-4) Of the 12 aspects that reached consensus, 10 were perceived as advantages of digital trials, which included a) the adoption of different study designs, including b) adaptive designs, as adaptation rules can be . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 5, 2022. performed automatically and remotely whether data are collected and analyzed by mobile tES systems. Panelists also considered that c) tES devices are already sufficiently developed to be used remotely, which allows for d) longer follow-up periods and e) higher recruitment rates, being f) faster and more efficient than on-site trials. Also, g) greater external validity compared to on-site trials were perceived. Finally, other advantages were the potential for h) collecting more data than on-site trials, i) combination with other therapies, and j) scalability. The 2 disadvantages / challenges that reached consensus were: a) the necessity of validating new tES parameters, methodologies, and indications first in on-site studies, and b) the need of developing better remote assessment methods, such as behavioral clinical scales properly designed and validated to be employed remotely. The items that did not reach consensus mostly pertain to internal validity issues. Interestingly, a significant portion of panelists were undecided on these issues (figure 5). Of note, interesting remarks (detailed in Sup. Material -Appendix 10) were made for: a) randomization-allocation procedures that are done using either specific devices or apps/softwares, but can be vulnerable to contamination biases due to hacking and exposure of the randomization list; b) study blinding, as blinding breaking can occur if devices are manipulated; c) sham stimulation, which can also be revealed due to device manipulation. The panelists recommended that teams performing tES digital trials should have members specialized in: a) digital marketing strategies, to enhance online recruitment; b) data science and visualization, for data collection and analysis; c) front-end interfaces, to enhance user experience; d) back-end programming; e) issues related to data security, integrity, anonymity, and replicability 25, 26 . Also, they suggested that f) a team member should be always ("24/7") available (figure 5). Regarding further research, most panelists recommended that better methods for (a) randomization / allocation, and (b) sham should be explored. Also, further research was recommended to develop or refine methods to enhance (c) adherence and (d) external validity of the trials. Also, more research should be devoted to aspects such as (e) combination of interventions, (f) biobehavioral data collection, (g) enhanced data security, and methods to assess (h) serious and (i) unexpected adverse events (details in Sup. Material -Appendix 11). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 5, 2022. ; https://doi.org/10.1101/2022.03.03.22271837 doi: medRxiv preprint By convening a diverse group of 61 worldwide specialists in the field of non-invasive neuromodulation, we performed the first systematic assessment and Delphi-based validation of perceived challenges, opportunities, methodological issues, and recommendations on digitizing non-invasive neuromodulation trials. We used several strategies to organize and describe these assessments, such as processing mapping strategies, a systematic scoping review of the literature, iterative rating and validation of structured questionnaires by specialists, and assessment of the digital readiness of commercial tES devices. Taken together, our findings show that performing digital trials using mobile tES devices has complementary advantages and can overcome major on-site tES trial challenges, namely the intensive treatment schedules 23 , transportation costs, accessibility, and scalability 8 . By performing trials remotely, dislocation burdens are decreased, as well as the need for space at the research center, and of trained staff for delivering tES sessions, aspects that increase trial duration 6, 59 . Additionally, tES devices are highly scalable, as a single team member can monitor several people at once, provided that tES devices are easy to manipulate, handle, and can be self-delivered. Such scalability gains could be leveraged in faster trials with larger sample sizes, longer follow-up periods, and employing digital recruitment strategies. Considering our results, we propose and further discuss a conceptual framework for digitizing neuromodulation, combining concepts of digital clinical trials with mobile tES (figure 6). To the best of our knowledge, the term "mobile tES" has not been used yet to describe the combination of highly-deployable neuromodulation devices paired with other wearables or apps. This terminology frames tES in the context of mobile Health devices 57 , encouraging the exploitation of contact points between these two growing fields. However, even though several issues for deployable and remote use have already been addressed (eg, decreasing prices, rechargeable batteries, tailored sponges, sham stimulation, easiness of electrode positioning and of programming session stimulation parameters), our findings showed that no commercial tES devices have been fully digitized yet, presenting different degrees of online, wired, or wireless connectivity. Also, especially for offline devices, methods for restricting the number of sessions allowed per day were not identified. Additionally, most systems neither collect active or passive data, nor present friendly-user interfaces. The panelists agreed on several opportunities; however, most are distant from immediate implementation. For instance, device-to-device communication ("Internet of Things") would need pairing with third-party apps . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 5, 2022. ; https://doi.org/10.1101/2022.03.03.22271837 doi: medRxiv preprint or wearables, which is not yet available. This limits other perceived opportunities such as digital phenotyping, combination with psychological or cognitive app interventions, and seamless automatization with other platforms and digital processes. The impact of digitizing neuromodulation trials on external validity seems mostly positive, considering that subjects who would not be enrolled in on-site trials are reached. In fact, on-site trial samples are likely to be composed by those with free time and/or living near the clinical center to receive the sessions. Notwithstanding, it is still possible that those younger, richer, more educated, with higher digital literacy, and living in urban areas are preferentially enrolled in digital trials. Also, if recruitment strategies are performed solely using social media, the trial results would have restricted generalizability for people that do not use such media. This could be overcome by using segmented digital marketing campaigns. Likewise, attrition rates might not necessarily be lower in digital trials -although not needing to return daily to the clinical center could decrease burden and minimize dropouts, samples from digital trials might face less engagement and more difficulties in self-delivering the sessions. The lack of daily contact with the clinical staff could also decrease motivation and increase dropouts. In addition, direct social contact, social support and social connectedness outside the digital environment can influence attrition rates of clinical trials. Therefore, tele-monitoring and proper interaction with participants, managing their expectations and credibility of the team, and reinforcing the need to abide by the study protocol, could avoid dropouts. Panelists also emphasized that methodological issues that have not been completely addressed in on-site trials can be magnified in digital trials 14, 26 . For instance, if the process of randomization -allocation concealment -is hacked from the server and publicly exposed, the entire trial can be lost (or, at least, suspended until a new list is generated). Moreover, blinding and sham stimulation issues are not completely resolved issues in on-site trials 60 , and biases arising from these steps are more likely to occur (eg, sham stimulation can be unconcealed by measuring the voltage between electrodes 9 ) and harm the entire study (for example, by exposing methodological vulnerabilities on the Web). Additionally, issues that would be minor in on-site trials might be more relevant in online trials. For instance, stimulation sessions can be performed in on-site trials appropriately and guarantee adherence 9 , but, in digital trials, some degree of remote monitoring would be necessary for ensuring these aspects. Finally, there are unique new challenges for digitizing neuromodulation. Even though cyber-hacking is not usually discussed in the environment of clinical trials, government and big company systems are being increasingly hacked. Data anonymity and confidentiality are additional aspects of vulnerability more relevant than in on-site trials, if, for instance, information is also recorded in the devices, smartphones, or is . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 5, 2022. ; https://doi.org/10.1101/2022.03.03.22271837 doi: medRxiv preprint transmitted remotely. Data collection using standard behavioral scales (for instance, scales for depression) and adverse events need to be further validated to be used online and remotely to avoid instrumental biases. Finally, even open pre-publication of study protocols, which enhances transparency and reproducibility, cannot be fully detailed in digital trials, as a complete description of the groups, blinding methods, and sham stimulation of the protocols could be harmful to the internal validity of digital trials 8, 14 . Although we systematically reviewed the literature for selecting the most productive authors in neuromodulation, experts publishing in non-English databases might not have been selected. In addition, most of the panelists are from high-income countries, limiting the experience, feedback, and number of votes of panelists from low-/middle-income countries, where 85% of the world population lives, and with probably additional issues on digitalization, including availability. Moreover, our search might not have identified emerging young experts as we have established a threshold based on the number of publications. Although we considered different methods for composing the EP, such as "snowball sampling" based on recommendations from the SC members, and search of other databases such as clinicaltrials.gov, preprints and conference publications, these processes would be non-systematic or involve gray areas in the literature. We also did not assess other stakeholders besides people from industry and academia that could have been relevant for our work, such as patients, governmental and nongovernmental organizations. Moreover, only 8 of 13 companies replied to our contacts, despite several emails that were sent to reach them, and even offering the possibility of online meetings to discuss this work. Although we could have extracted company information based on public information, we opted for not doing that as some information could have been inaccurate. Finally, no large tES digital trials have been finished and published yet; therefore, the processes and challenges described here are mostly theoretical and should be iteratively updated as the field develops. Interestingly, the lack of consensus on issues related to its disadvantages, risks, and biases, with many specialists remaining undecided, indicates that the field is still in its infancy. The recommendations for teams conducting digital neuromodulation trials markedly diverge from on-site trials that are centered on clinical specialists and staff trained in performing biomedical procedures. The feasibility of these recommendations should be further debated, as they would require more resources. In fact, most recommendations fit with companies and for pivotal studies, and not necessarily for teams running pilot studies that would not have all the capabilities recommended above. For instance, third-party services could be contracted to do specific tasks related to software and hardware development, or such aspects could be developed together by researchers and companies. Moreover, recommendations such as . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 5, 2022. ; https://doi.org/10.1101/2022.03.03.22271837 doi: medRxiv preprint a support team being always available for medical urgencies, although optimal, might be unrealistic even with large resources. Such issues would need to be carefully discussed with internal review boards and ethics committees to guarantee patient safety without harming trial feasibility. The recommendations for further research in some aspects specifically related to internal validity, and also external validity, were largely convergent, reaching 70-80% agreement rates. Taken together, these recommendations call for new standards and best practices of fundamental pillars of tES clinical research, such as methods for sham stimulation, randomization, allocation and assessment of adverse events. In fact, these methodologies have been steadily built over the last decade 6,7,10 and, although challenged in certain aspects such as sham and blinding 60,61 , they have been largely used in clinical trials 26 . Although several approaches could be used, in a first step relatively simple randomized studies involving healthy participants could use parameters such as blinding efficacy and rate of adverse events as outcome measures, comparing whether they are different in those receiving on-site vs. online tES. Pilot studies using mobile tES in clinical samples are also encouraged to report their methodological approaches and challenges 62,63 . In this first Delphi Panel evaluating opportunities, risks, and methodological issues regarding digitizing tES trials, we provided a landscape of this new approach and reached consensus on several recommendations that should be evaluated in further studies. The panel of specialists agreed on advantages associated with the implementation of tES trials; however, considering the fast-growing digitalization in Medicine and Biotechnology, there is a pressing need to better understand how to adapt tES trials to be performed remotely, with a clearer knowledge regarding its positive and negative aspects. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 5, 2022. ; https://doi.org/10.1101/2022.03.03.22271837 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 5, 2022 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 5, 2022. ; https://doi.org/10.1101/2022.03.03.22271837 doi: medRxiv preprint pre-screening, potential participants can be scheduled and contacted automatically for online screening (a step that can be enriched by using machine learning algorithms); c) screening, enrolled participants can provide digital consent, have transcranial electric stimulation (tES) devices shipped to their homes, and being instructed how to use them via videos and/or augmented reality techniques; and d) participation in the trial, interaction with the staff can be mediated by psychiatric chatbots for filtering between simple questions, reporting of adverse events and need of medical care. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 5, 2022 F i g u r e 1 : S t u d y w o r k f l o w . F i r s t , t h e s t e e r i n g c o m m i t t e e ( S C ) w a s f o r m e d , i n c l u d i n g p r o m i n e n t r e s e a r c h e r s i n t h e f i e l d s u p p l e m e n t e d b y t h e r e s u l t s o f a s y s t e m a t i c r e v i e w c o n d u c t e d o n t E S t r i a l s , t h e S C d e v e l o p e d t h e q u e s t i o n n a i r e , w h i c h w t o a l l p a r t i c i p a n t s o f t h e s t u d y ( S C a n d e x p e r t p a n e l ( E P ) ) t o a n s w e r i t . S i m u l t a n e o u s l y , c o m p a n i e s p r o d u c i n g t E S d e v i c e c o n t a c t e d , b a s e d o n t h e c o m p a n i e s k n o w n b y t h e S C a n d E P , t o p r o v i d e d e t a i l s a b o u t t h e a v a i l a b l e d e v i c e s . F i n a l l y , a n a l y z e d t h e d a t a r e c e i v e d f r o m t h e q u e s t i o n n a i r e a n d a l l p a r t i c i p a n t s t o o k p a r t i n r e p o r t i n g t h e r e s u l t s . 23 d . T h e n , w a s s e n t e s w e r e t h e S C . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 5, 2022. ; Figure 2 : Digitalization readiness of tES devices. Based on the feedback of 8 out of 13 major transcranial e current stimulation (tES) companies, we evaluated the readiness of these systems for digital trials, considerin connectivity (capability of communicating with other devices and the Web, due to presence of Bluetooth, 3G/4G/5G, and communication with third-party apps), methodological aspects (randomization, sham, blinding, data collection, optional data collection, and optional research dashboard), parameter space flexibility (c intensity, session duration, number of sessions, electrode positioning), ecological footprint (rechargeabilit replaceability of batteries, recyclability and reusability of sponges, and recyclability of devices), front-end int (smartphone app, touch screen, device itself, no interaction), and data security (compliance to laws such as G mention of encryption and anonymization procedures, and option for not collecting sensitive data). The question and rating systems are described in the Sup.Material-Appendix 5. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 5, 2022 p a r t i c i p a n t s ( 2 4 f r o m t h e s t e e r i n g c o m m i t t e e a n d 3 1 f r o m t h e e x p e r t p a n e l ) f o r t h e p t E S c l i n i c a l t r i a l s s t r e n g t h s a n d o p p o r t u n i t i e s t h r e a t s a n d w e a k n e s s e s ( B ) . E a c h i t e m w a s r a t e d f r o m s t r o n g l y d i s a g r e e t o s t r o n g l y a g r e e . I n r a t i n g s f o r t h e p o t e n t i a l s t r e n g o p p o r t u n i t i e s o f t E S c l i n i c a l t r i a l s ( A ) , a l l o f t h e i t e m s h a v e r e a c h e d t h e 5 0 % t h r e s h o l d o f a g r e e m e n t ( r a t e d a s e i t h e r a g r e e o r s t r o n g l y a m o r e t h a n 5 0 % o f t h e r e s p o n d e n t s ) . T h e s e i t e m s h a v e a l s o r e a c h e d a m o r e s t r i n g e n t t h r e s h o l d o f 6 0 % . H o w e v e r , i n r a t i n g s f o r t h e . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 5, 2022 e e r i n g c o m m i t t e e a n d 3 1 f r o m t h e e x p e r t p a n e l ) f o r m e t h o d o l o g i c a l a s p e c t s o f t E S . E a c h i t e m w a s r a t e d f r o m s t r o n g l y d i s a g r e e t o a g r e e . I n r a t i n g s f o r t h e a d v a n t a g e s o f t r a n s c r a n i a l e l e c t r i c s t i m u l a t i o n ( t E S ) d i g i t a l t r i a l s f r o m a m e t h o d o l o g i c a l p e r s p e c t i v e , o n l y o n e i t G r e a t e r i n t e r n a l v a l i d i t y ) d i d n o t r e a c h t h e a g r e e m e n t t h r e s h o l d o f 5 0 % ( r a t e d a s e i t h e r a g r e e o r s t r o n g l y a g r e e b y m o r e t h a n 5 0 % r e s p o n d e n t s ) . A l l o f t h e o t h e r i t e m s i n t h i s c a t e g o r y a l s o r e a c h e d a m o r e s t r i n g e n t t h r e s h o l d o f 6 0 % . H o w e v e r , i n r a t i n g s f o r c h a l l e n g . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) T h i s f i g u r e d e p i c t s t h e r 5 5 p a r t i c i p a n t s ( 2 4 f r o m t h e s t e e r i n g c o m m i t t e e a n d 3 1 f r o m t h e e x p e r t p a n e l ) f o r t h e p t E S c l i n i c a l t r i a l s t e a m f e a t u r e s ( A ) a n d r e c o m m e n d a t i o n s f o r d i g i t i z i n g p t E S c l i n i c a l t r i a l s ( B ) . E a c h i t e m w a s r a t e d f r o m s t r o n g l y d i s a g r e e t o s t r o n g l y a g r e e . I n r a t i n g s f o r t c l i n i c a l t r i a l s t e a m f e a t u r e s ( A ) , a l l o f t h e i t e m s h a v e r e a c h e d t h e 5 0 % t h r e s h o l d o f a g r e e m e n t ( r a t e d a s e i t h e r a g r e e o r s t r o n g l y a g r e e t h a n 5 0 % o f t h e r e s p o n d e n t s ) . T h e s e i t e m s h a v e a l s o r e a c h e d a m o r e s t r i n g e n t t h r e s h o l d o f 6 0 % . S i m i l a r l y , i n r a t i n g s f o r t h e r e c o m m e n d a t i o n s f o r d i g i t i z i n g p t E S c l i n i c a l t r i a l s ( B ) , a l l o f t h e i t e m s h a v e r e a c h e d t h e 5 0 % t h r e s h o l d o f a g r e e m e n t . H o w e v e r , w i t h s t r i n g e n t t h r e s h o l d o f 6 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 5, 2022 s t i m u l a t i o n d e v i c e s h a d b e e n r e l a t i v e l y s i m p l e , e s s e n t i a l l y u s i n g b a t t e r i e s c o n n e c t e d t o e l e c t r o d e s t o d e l i v e r c o n s t a n t c u r r e n t s , a n d c o n t a i n f e w ( m i c r o ) e l e c t r o n i c c o m p o n e n t s . A l t h o u g h p o r t a b l e a n d s a f e , t h e y h a d n o t b e e n s p e c i f i c a l l y d e s i g n e d f o r u s e o u t s i d e h o s p i t a l o r a c a d e m i c c e n t e r s e t t i n g s . N e w a n d f u t u r e g e n e r a t i o n s o f t E S w i l l b e m o b i l e H e a l t h t E S s y s t e m s u s i n g d i g i t a l t e c h n o l o g i e s f o r i m p r o v i n g h e a l t h o u t c o m e s . T h e y a r e a n d w i l l b e s m a l l e r a n d l i g h t e r t h a n p r e v i o u s g e n e r a t i o n s , p o s s e s s i n g w i r e l e s s c o n n e c t i v i t y . S u c h d e v i c e s a r e a l r e a d y u s e d a t h o m e a n d a r e s e l f -d e l i v e r e d , u s u a l l y w i t h s o m e d e g r e e o f r e m o t . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 5, 2022. ; https://doi.org/10.1101/2022.03.03.22271837 doi: medRxiv preprint Evidence-based guidelines and secondary metaanalysis for the use of transcranial direct current stimulation (tDCS) in neurological and psychiatric disorders Regulatory Considerations for the Clinical and Research Use of Transcranial Direct Current Stimulation (tDCS): review and recommendations from an expert panel Limited output transcranial electrical stimulation (LOTES-2017): Engineering principles, regulatory statutes, and industry standards for wellness, over-thecounter, or prescription devices with low risk Clinical research with transcranial direct current stimulation (tDCS): challenges and future directions Rigor and reproducibility in research with transcranial electrical stimulation: An NIMH-sponsored workshop Supervised transcranial direct current stimulation (tDCS) at home: A guide for clinical research and practice A technical guide to tDCS, and related non-invasive brain stimulation tools Noninvasive brain stimulation in psychiatric disorders: A primer Digitizing clinical trials Digital phenotyping: a global tool for psychiatry New dimensions and new tools to realize the potential of RDoC: digital phenotyping via smartphones and connected devices Remotely-supervised transcranial direct current stimulation (tDCS) for clinical trials: guidelines for technology and protocols Factors supporting availability of home-based Neuromodulation using remote supervision in middle-income countries; Brazil experience The growing field of digital psychiatry: current evidence and the future of apps, social media, chatbots, and virtual reality Digitizing Portable Transcranial Electric Stimulation clinical trials: Scoping Review, Process Mapping, and recommendations from a Delphi Panel The Delphi Technique: Making Sense of Consensus A methodological checklist for fMRI drug cue reactivity studies: Development and expert consensus A Checklist for Assessing the Methodological Quality of Concurrent tES-fMRI Studies (ContES Checklist): A Consensus Study and Statement Scoping studies: advancing the methodology Thinking on Transcranial Direct Current Stimulation (tDCS) in Reading Interventions: Recommendations for Future Research Directions Strategies for replacing non-invasive brain stimulation sessions: recommendations for designing neurostimulation clinical trials Unmet Needs in Children With Attention Deficit Hyperactivity Disorder-Can Transcranial Direct Current Stimulation Fill the Gap? Promises and Ethical Challenges Cerebellar-cortical dysconnectivity in resting-state associated with sensorimotor tasks in schizophrenia Training in the practice of noninvasive brain stimulation: Recommendations from an IFCN committee The appropriate use of neurostimulation of the spinal cord and peripheral nervous system for the treatment of chronic pain and ischemic diseases: the Neuromodulation Appropriateness Consensus Committee Taking Sides: An Integrative Review of the Impact of Laterality and Polarity on Efficacy of Therapeutic Transcranial Direct Current Stimulation for Anomia in Chronic Poststroke Aphasia Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 2. Psychological Treatments Transcranial Electrical Stimulation Motor Evoked Potential Monitoring Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation (tDCS) Non-Invasive Brain Stimulation in Children With Unilateral Cerebral Palsy: A Protocol and Risk Mitigation Guide EAN guidelines on central neurostimulation therapy in chronic pain conditions Guidelines for TMS/tES Clinical Services and Research through the COVID-19 Pandemic Low intensity transcranial electric stimulation: Safety, ethical, legal regulatory and application guidelines Effects of transcranial stimulation in developmental neurocognitive disorders: A critical appraisal Past, present, and future of non-invasive brain stimulation approaches to treat cognitive impairment in neurodegenerative diseases: Time for a comprehensive critical review A Critical Review and Synthesis of Clinical and Neurocognitive Effects of Noninvasive Neuromodulation Antidepressant Therapies Non-invasive and invasive brain stimulation in alcohol use disorders: A critical review of selected human evidence and methodological considerations to guide future research Promoting Creativity Through Transcranial Direct Current Stimulation (tDCS). A Critical Review Use of non-invasive stimulation in movement disorders: a critical review Value and Efficacy of Transcranial Direct Current Stimulation in the Cognitive Rehabilitation: A Critical Review Since Tolerability and Blinding of Transcranial Direct Current Stimulation in People with Parkinson's Disease: A Critical Review Transcranial direct current stimulation (tDCS) to improve naming ability in post-stroke aphasia: A critical review Clinical trial design in non-invasive brain stimulation psychiatric research Safety of Transcranial Direct Current Stimulation: Evidence Based Update Neuromodulation of chronic headaches: position statement from the European Headache Federation Non-invasive Cerebellar Stimulation-a Consensus Paper Effects of tDCS on motor learning and memory formation: A consensus and critical position paper Latin American and Caribbean consensus on noninvasive central nervous system neuromodulation for chronic pain management (LAC2-NIN-CP) Safety and acceptability of transcranial direct current stimulation for the acute treatment of major depressive episodes: Analysis of individual patient data Human-Centered Design Strategies for Device Selection in mHealth Programs: Development of a Novel Framework and Case Study FDA Regulation and Approval of Medical Devices: 1976-2020 The combination of medical devices and medicinal products revisited from the new European legal framework Innovation process of mHealth: An overview of FDA-approved mobile medical applications Challenges With Developing Secure Mobile Health Applications: Systematic Review Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 4. Neurostimulation Treatments Sham tDCS: A hidden source of variability? Reflections for further blinded, controlled trials Is the 'end-of-study guess' a valid measure of sham blinding during transcranial direct current stimulation? Telehealth transcranial direct current stimulation for recovery from Post-Acute Sequelae of SARS-CoV-2 (PASC) Pilot trial of home-administered transcranial direct current stimulation for the treatment of depression